124.38
-0.21 (-0.17%)
| Penutupan Terdahulu | 124.59 |
| Buka | 124.50 |
| Jumlah Dagangan | 215,030 |
| Purata Dagangan (3B) | 748,836 |
| Modal Pasaran | 7,544,741,376 |
| Harga / Pendapatan (P/E Ke hadapan) | 6.51 |
| Harga / Jualan (P/S) | 1.96 |
| Harga / Buku (P/B) | 2.12 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | 11.86% |
| Margin Operasi (TTM) | -2.90% |
| EPS Cair (TTM) | 7.37 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -0.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 103.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 129.82% |
| Nisbah Semasa (MRQ) | 3.38 |
| Aliran Tunai Operasi (OCF TTM) | 1.56 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.50 B |
| Pulangan Atas Aset (ROA TTM) | 3.99% |
| Pulangan Atas Ekuiti (ROE TTM) | 12.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Jazz Pharmaceuticals plc | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 2.63 |
|
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.04% |
| % Dimiliki oleh Institusi | 101.22% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 205.00 (Truist Securities, 64.82%) | Beli |
| Median | 185.00 (48.74%) | |
| Rendah | 151.00 (RBC Capital, 21.40%) | Beli |
| Purata | 181.20 (45.68%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 126.45 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 29 Aug 2025 | 185.00 (48.74%) | Beli | 127.75 |
| Morgan Stanley | 28 Aug 2025 | 163.00 (31.05%) | Beli | 126.13 |
| 06 Aug 2025 | 162.00 (30.25%) | Beli | 105.93 | |
| Needham | 28 Aug 2025 | 202.00 (62.41%) | Beli | 126.13 |
| 20 Aug 2025 | 202.00 (62.41%) | Beli | 119.07 | |
| RBC Capital | 28 Aug 2025 | 151.00 (21.40%) | Beli | 126.13 |
| Truist Securities | 28 Aug 2025 | 205.00 (64.82%) | Beli | 126.13 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |